NCT06028633View on ClinicalTrials.gov

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2026

Conditions

Advanced Non-squamous Non-small-cell Lung CancerRecurrent Non-Squamous Non-Small Cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer

Interventions

DRUG

pembrolizumab

pembrolizumab 200mg IV on day 1 for every 3 weeks

DRUG

lenvatinib

lenvatinib 8mg taken orally every day

DRUG

albumin-bound paclitaxel

albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks

Trial Locations (1)

100034

Peking University First Hospital Ethics Committee, Beijing

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Peking University First Hospital

OTHER

NCT06028633 - Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | Biotech Hunter | Biotech Hunter